NCT03811080 - Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease | Biotech Hunter

Enrollment

327

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions

Non-Erosive Gastroesophageal Reflux Disease

Interventions

DRUG

DWP14012 A mg

The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.

DRUG

DWP14012 B mg

The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.

DRUG

Placebo

The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.

Trial Locations (1)

Unknown

RECRUITING

Hanyang University Medical Center, Seoul